Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Viral Immunology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1435873

This article is part of the Research Topic Treatment for COVID-19 across the possible use of monoclonal antibodies and antiviral agents: clinical, epidemiological, virological, and immunological aspects View all 10 articles

Intersecting SARS-CoV-2 Spike Mutations & Global Vaccine Efficacy Against COVID-19

Provisionally accepted
  • 1 University of Technology Sydney, Sydney, New South Wales, Australia
  • 2 University of Tabriz, Tabriz, East Azerbaijan, Iran
  • 3 University of Tehran, Tehran, Tehran, Iran
  • 4 John A. Burns School of Medicine, University of Hawaii at Mānoa, Honolulu, United States
  • 5 Islamic Azad University of Mashhad, Mashhad, Iran
  • 6 Isfahan University of Medical Sciences, Isfahan, Isfahan, Iran
  • 7 Shahid Bahonar University of Kerman, Kerman, Kerman, Iran
  • 8 Science and Research Branch, Islamic Azad University, Tehran, Tehran, Iran
  • 9 Zhengzhou University, Zhengzhou, Henan Province, China
  • 10 Woolcock Institute of Medical Research, Sydney, New South Wales, Australia

The final, formatted version of the article will be published soon.

    In line with encountering the world with the emergence of vaccine-resistance variants of SARS-CoV-2, 15,669,529 COVID-19 vaccines received samples until April 2023 are investigated as two doses in the first phase and booster vaccinations in the second phase. The analysis shows that D614G and P681 mutations occurred in both phases. The E484 and Y655 mutations significantly emerged during the second phase. The 762-889 and 254-381 regions are revealed as conserved parts and could be considered in vaccine design. The Kruskal-Wallis test revealed a significant reduction in single mutations between populations with 20-50% and those with 70-100% vaccination coverage (p=0.017). The Mann-Whitney U test proposes a link between vaccination and suppression of viral mutation rates.Dynamic modeling suggests that key mutations have facilitated the virus's evolution and immune escape. The study's findings are crucial for understanding virus genome mutations, especially E614 and P681 in Delta and E484 and H655 in Omicron. This highlights the need to adjust strategies and strengthen global efforts in combating the pandemic.

    Keywords: D614G, P681, E484, Y655, Mutation, SARS-CoV-2

    Received: 21 May 2024; Accepted: 12 Feb 2025.

    Copyright: © 2025 Tokhanbigli, Salami Ghaleh, Rahimian, Mahmanzar, Bayat, Ahangarzadeh, Moradi, Mahmanzar, Wang, Oliver and Deng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yunliang Wang, Zhengzhou University, Zhengzhou, 450001, Henan Province, China
    Brian Gregory George Oliver, Woolcock Institute of Medical Research, Sydney, New South Wales, Australia
    Youping Deng, John A. Burns School of Medicine, University of Hawaii at Mānoa, Honolulu, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more